ClinicalTrials.gg
Not yet recruitingNCT07796204Updated Sep 1, 2026

Ability of Almonds to Improve Nutrition During GLP-1 Treatment

An interventional study of Almond Diet in Obesity and Type 2 Diabetes, sponsored by Pennington Biomedical Research Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Pennington Biomedical Research Center · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 67 studies in Obesity by Pennington Biomedical Research Center — 9 open to participants now, 13 under way, none of them phase 3. Obesity · Pennington Biomedical Research Center.

Planned enrollment
13th of 45
76 · median 42
Started
2026
with 4 others
No phase
36 of 67
5 open now
Primary completion
2028-06
later than 10 of 12 live
Registered
66th of 67
by date

Among the 67 studies in Obesity by Pennington Biomedical Research Center, this one is the 13th largest by planned enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2026, is one of 36 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 66th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 67 studies in Obesity by Pennington Biomedical Research Center are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Obesity by Pennington Biomedical Research Center, or all of them as a file.
02

Study summary

This 8-week randomized controlled pilot trial is to test the hypothesis that, compared to a Usual Diet control group, almond intake will increase vitamin E (alpha-tocopherol) levels in the blood and improve diet quality (Healthy Eating Index) among people prescribed a glucagon-like peptide-1. Two groups of individuals will either: 1) consume a minimum of 56 grams of almonds each day, or 2) not consume almonds and follow their usual diet.

03

Conditions studied

  • Obesity
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-70 years
  • ≥ 27 kg/m2 - 47.5 kg/m2 and diagnosed with type 2 diabetes by their personal physician (e.g., primary care physician, endocrinologist), or BMI ≥ 30 kg/m2 and have obesity and stable access (i.e., at least a two-month supply) to the medication
  • Prescribed branded injectable semaglutide or injectable tirzepatide (medication will not be provided as part of the study)
  • will be measured at Pennington Biomedical at baseline (and follow-up), though the baseline HbA1c levels from Pennington Biomedical will not be used for eligibility criteria
  • Use of other medications (diabetes medications or otherwise) are permitted at the discretion of the Medical Investigator
  • Enroll and complete baseline assessments prior to starting pharmacotherapy
  • Able and willing to adhere to all study-related procedures

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Taking or planning to take during the trial a medication, vitamin, or mineral supplement that affects vitamin E levels
  • Previous use of a glucagon-like peptide-1 medication in the last 3 months
  • to glucagon-like peptide-1 medication use or previous adverse reaction/allergy to a glucagon-like peptide-1 receptor agonist medication
  • Medical, psychological, cognitive, or other conditions that limit the ability to complete study procedure
  • History of bariatric surgery
  • Allergic to almonds
  • Active , excluding some skin cancers, or undergoing chemotherapy/radiotherapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Almond Diet Group

    This group will be provided with up to 84 grams per day of raw or roasted almonds per day and coached to consume at least 56 grams/day. Participants will be instructed to consume the almonds by replacing snacks, particularly those high in refined carbohydrate, with almonds; integrating almonds into other snacks and meals, etc. 56 grams/day of almonds is equivalent to two servings, which reflects the adult Dietary Guidelines for Americans and is consistent with doses that have been shown to increase alpha-tocopherol levels, and produce beneficial effects on cardiometabolic health and nutrient intake.

    Other: Almond Diet

  • No intervention
    Usual Diet Control

    This group will not be provided with any food products and will not receive dietary advice, except being asked to abstain from eating nuts during the 8-week trial. They will receive a weekly phone call from the study team to foster retention and to control the number of contacts between the study team and each of the two groups in the trial.

Interventions

  • OtherAlmond Diet

    Participants on a glucagon-like peptide-1 medication will be provided with up to 84 grams per day of almonds and coached to consume at least 56 grams per day.

06

What researchers measure

Primary outcomes

  1. Vitamin E

    alpha-tocopherol measured in blood

    Time frame: 8 weeks

  2. Diet Quality

    Healthy Eating Index assessed with the Remote Food Photography Method and SmartIntake app

    Time frame: 8 weeks

07

Study locations

1 site
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70806, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2028, 20 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 20 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2026
First posted
Sep 1, 2026
StartEst.
Sep 3, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07796204
Collaborators
Almond Board of California
Responsible party
Corby K. Martin (Professor, Director, Ingestive Behavior Laboratory, Pennington Biomedical Research Center) — Principal investigator
First posted
Sep 1, 2026
Start date
Sep 3, 2026 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Corby K Martin, PhD
Contact
corby.martin@pbrc.edu
225-763-2585
Corby K Martin, PhD
principal investigator · Pennington Biomedical Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion